Molecular Templates, Inc. to Present Interim Data and Host

AUSTIN, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical firm centered on the invention and growth of proprietary focused biologic therapeutics, engineered toxin our bodies (ETBs), right now introduced that it’ll current 4 abstracts and host an in-person Research & Development Day, Friday, November 11, 2022, at The Society for Immunotherapy of Cancer’s (SITC) 37^th Annual Meeting which shall be held November 8 – 12, 2022 on the Boston Convention and Exhibition Center in Boston, MA.

The R&D Day occasion will embody in-person displays by the senior management workforce of Molecular Templates reviewing the expertise of next-generation ETBs, the scientific highlights informing growth methods, and the information introduced at SITC round its PD-L1 focusing on MT-6402 and CTLA-4 focusing on MT-8421 applications. The occasion shall be webcasted and happen 11:30am – 12:30pm ET Friday, November 11, 2022, on the Boston Convention Center throughout SITC’s 37^th Annual Meeting. A dwell Q&A session will comply with the presentation.

Four abstracts to be introduced at SITC embody:

Title: A scientific stage engineered toxin physique (ETB) focusing on PD-L1 (MT-6402) induces peripheral pharmacodynamic responses distinctive from PD-L1 monoclonal antibodies
Program: MT-6402, PD
Abstract Number: 736
Date: Friday, Nov 11, 2022
Location: Hall C

Title: First-in-human, dose escalation and growth examine of MT-6402, a novel engineered toxin physique (ETB) focusing on PD-L1, in sufferers with PD-L1 expressing relapsed/refractory superior stable tumors: Interim Data
Program: MT-6402, Clinical
Abstract Number: 764
Date: Friday, Nov 11, 2022
Location: Hall C

Title: Engineered toxin physique focusing on CTLA-4 (MT-8421) depletes Tregs within the tumor microenvironment and synergizes with αPD-1 to improve T cell immunity 
Program: MT-8421
Abstract Number 817
Date: Thursday, Nov 10, 2022
Location: Hall C

Title: Engineered toxin physique focusing on TIGIT depletes Tregs within the tumor microenvironment and reduces tumor burden in mice 
Program: TIGIT
Abstract Number 1379
Date: Thursday, Nov 10, 2022
Location: Hall C

“We look forward to updating the community on data presented at SITC. We believe the approach MTEM has taken in immuno-oncology is highly differentiated and that we are seeing early signs this approach can provide patient benefit and open up new avenues for targeting PD-L1 and CTLA-4,” stated Eric Poma, Chief Executive Officer of Molecular Templates.

To register for the webcast, please click on right here.

About Molecular Templates

Molecular Templates is a clinical-stage biopharmaceutical firm centered on the invention and growth of focused biologic therapeutics. Our proprietary drug platform expertise, generally known as engineered toxin our bodies, or ETBs, leverages the resident biology of a genetically engineered type of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of motion for most cancers and different severe illnesses.

Forward-Looking Statements

This press launch accommodates forward-looking statements for functions of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to replace these forward-looking statements and claims the safety of the Act’s Safe Harbor for forward-looking statements.  All statements, aside from statements of historic information, included on this press launch concerning technique, future operations, future monetary place, future income, projected bills, prospects, plans and aims of administration are forward-looking statements. In addition, when or if used on this press launch, the phrases “potential,” “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and comparable expressions and their variants, as they relate to Molecular Templates could establish forward-looking statements. Examples of such statements embody, however usually are not restricted to, statements concerning the security or potential efficacy of Molecular Templates’ drug or biologic candidates, together with the anticipated advantages of MT-6402, MT-5111, MT-0169, and MT-8421 and Molecular Templates’ next-generation ETBs; statements relating to the event of MT-6402, MT-5111, MT-0169, MT-8421 and next-generation ETBs; the anticipated timing for submitting numerous IND functions and conducting research, opening websites and producing information; the anticipated participation and presentation at upcoming conferences; the anticipated timing for offering updates on MT-6402, MT-5111, MT-0169, and MT-8421, in addition to Molecular Templates’ earlier stage pipeline of ETBs, together with any pre-clinical information; and Molecular Templates’ perception that its proprietary biologic drug platform expertise, or ETBs, supplies for a differentiated mechanism of motion for most cancers and different severe illnesses.

Forward-looking statements usually are not ensures of future efficiency and contain dangers and uncertainties. Actual occasions or outcomes could differ materially from these mentioned within the forward-looking statements on account of numerous components together with, however not restricted to, the uncertainties inherent within the preclinical and scientific growth course of; whether or not Molecular Templates’ money sources shall be enough to fund its persevering with operations for the durations and/or trials anticipated; Molecular Templates’ means to well timed enroll sufferers in its scientific trials; the power of Molecular Templates’ to shield its mental property rights; dangers from world pandemics together with COVID-19; and legislative, regulatory, political and financial developments, in addition to these dangers recognized below the heading “Risk Factors” in Molecular Templates’ filings with the SEC. There might be no assurance that any of Molecular Templates’ drug or biologic candidates shall be efficiently developed, manufactured or commercialized, that remaining outcomes of scientific trials shall be supportive of regulatory approvals required to market merchandise, or that any of the forward-looking data offered herein shall be confirmed correct. Any forward-looking statements contained on this press launch converse solely as of the date hereof, and Molecular Templates particularly disclaims any obligation to replace any forward-looking assertion, whether or not due to new data, future occasions or in any other case.

Contact:

Dr. Grace Kim
Head of Investor Relations
[email protected]